Provided by Tiger Trade Technology Pte. Ltd.

ZYMEWORKS INC (US)

25.15
-0.8100-3.12%
Post-market: 25.150.00000.00%19:30 EDT
Volume:844.45K
Turnover:21.41M
Market Cap:1.78B
PE:-12.45
High:26.19
Open:26.18
Low:25.04
Close:25.96
52wk High:31.34
52wk Low:16.00
Shares:70.96M
Float Shares:66.63M
Volume Ratio:0.72
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0200
EPS(LYR):-1.0800
ROE:-72.31%
ROA:-24.14%
PB:22.21
PE(LYR):-23.29

Loading ...

Quince Therapeutics Names Leone Patterson Audit, Compensation Committee Chair in Board Overhaul

Reuters
·
Yesterday

Vir Biotechnology Names Aziz Sawaf as CFO Effective Oct. 5, 2026

Reuters
·
Oct 01

Zymeworks is Maintained at Buy by Citigroup

Dow Jones
·
Sep 30

Zymeworks Inc. : TD Cowen Reinstates Coverage with Buy Rating; Price Target $34

THOMSON REUTERS
·
Sep 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 29

Zymeworks price target raised to $39 from $38 at Citi

TIPRANKS
·
Sep 29

Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

MT Newswires Live
·
Sep 28

GUIDANCE: (ZYME) Zymeworks Expects 2026 Revenue Range $278M - $292M

MT Newswires Live
·
Sep 28

Zymeworks announces financial impact of Theravance Biopharma acquisition

TIPRANKS
·
Sep 28

Zymeworks Inc. - Expects Total Revenue, Including Collaboration Revenue from Yupelri, for 2026 to be Between $278 Mln and $292 Mln

THOMSON REUTERS
·
Sep 28

Zymeworks Inc. Fy2026 REV View $311.7 Mln

THOMSON REUTERS
·
Sep 28

Zymeworks Outlook 2026 Adjusted Ebitda to be Between $114 Mln and $128 Mln

THOMSON REUTERS
·
Sep 28

Zymeworks Q2 FY26 Net Loss Widens to $45 Million; Revenue Guidance Rises to $278 Million-$292 Million for FY26

Reuters
·
Sep 28

Press Release: Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Dow Jones
·
Sep 28

Zymeworks Completes Acquisition of Theravance Biopharma

THOMSON REUTERS
·
Sep 24

Zymeworks Initiated at Outperform by Wolfe Research

Dow Jones
·
Sep 17

Zymeworks initiated with an Outperform at Wolfe Research

TIPRANKS
·
Sep 17

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

TIPRANKS
·
Sep 10

Theravance Biopharma Announces Shareholder Meeting on Merger Deal

Reuters
·
Sep 10

Zymeworks (ZYME) Secures FDA Approval And $250 Million Milestone, Is The Stock Still Undervalued?

Simply Wall St.
·
Aug 27